Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects.
Komoroski B; Vachharajani N; Boulton D; Kornhauser D; Geraldes M; Li L; Pfister M; Clinical Pharmacology And Therapeutics, 2009, vol. 85, issue 5, p 520, ISSN 15326535. ISBN 15326535.

Full Text Resources Located for this Citation

View article on EBSCOhost(Login required)
View article via CrossRef